Transgene SA(TGNA)

Description: Transgene SA, a biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. It involved in developing TG4050, a therapeutic vaccine that is in Phase I clinical trial for the treatment of ovarian cancer, and head and neck cancers; TG4001, a therapeutic vaccine, which is in Phase II clinical trial for the treatment of HPV-positive cancers; TG6002, an oncolytic virus that is in Phase I/IIa clinical trial for the treatment of gastrointestinal and colorectal cancers; and BT-001, an oncolytic virus, which is in Phase I/II clinical trial for the treatment of solid tumors. The company also develops TG1050, a therapeutic vaccine for the treatment of hepatitis B; TG6050 for the treatment of non-small cell lung cancer, and Pexa-Vec, an oncolytic virus for the treatment of solid tumors. It has strategic collaboration agreements with AstraZeneca, Merck KGaA, Pfizer, and NEC Corporation; licensing agreements with SillaJen, Ascend BioPharmaceutical, and Valneva; and agreements with Merck & Co, Sanofi, BioInvent, and Randox. Transgene SA was incorporated in 1979 and is headquartered in Illkirch-Graffenstaden, France. Transgene SA is a subsidiary of TSGH SAS.

---

Keywords: Biotechnology Cancer Solid Tumors Treatment Of Cancer Non Small Cell Lung Cancer Ovarian Cancer Hepatitis B Virotherapy Head And Neck Cancer Treatment Of Non Small Cell Lung Cancer Cancer Vaccine Oncolytic Virus Treatment Of Ovarian Cancer Valneva Se Experimental Cancer Treatments Treatment Of Hepatitis B Mérieux Family Pexastimogene Devacirepvec Sillajen Therapeutic Vaccines Transgene Bt 001 Hpv Positive Cancers Tg6002 Treatment Of Hpv Positive Cancers

---

Home Page: www.transgene.fr

400, boulevard Gonthier d’Andernach
Illkirch-Graffenstaden, 67405
France
Phone: 33 3 88 27 91 00

---

Officers

Exchange: F

Country: DE : Germany

Currency: Euro (€)